NCM
TVRD

New Capital Management’s Tvardi Therapeutics TVRD Stock Holding History

New Capital Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Hold
0
– – – 155
2020
Q4 		– Hold
0
– – – 154
2020
Q3 		– Hold
0
– – – 127
2020
Q2 		– Hold
0
– – – 125
2020
Q1 		– Hold
0
– – – 137
2019
Q4 		– Hold
0
– – – 137
2019
Q3 		– Hold
0
– – – 136
2019
Q2 		– Hold
0
– – – 137
2019
Q1 		– Hold
0
– – – 138
2018
Q4 		– Sell
-4
Closed -$2.58K – 152
2018
Q3 		$4K Buy
+4
New +$2.89K 0.01% 136

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

New Capital Management's TVRD Position: Q1 2021 in Review

New Capital Management held its Tvardi Therapeutics (TVRD) position steady in Q1 2021 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #155.

New Capital Management first reported a position in TVRD in Q3 2018 and has held it in 1 quarter since. The position peaked at $4K in Q3 2018. 168 funds tracked by Wall St. Rank hold TVRD as of Q1 2021.

  • New Capital Management held 0 shares of Tvardi Therapeutics worth $0 as of Q1 2021.
  • New Capital Management left its Tvardi Therapeutics share count unchanged in Q1 2021.
  • Tvardi Therapeutics made up ﹤0.01% of New Capital Management's portfolio in Q1 2021, its #155 holding.
  • New Capital Management first reported a position in Tvardi Therapeutics in Q3 2018 and has held it in 1 quarter since.
  • New Capital Management's Tvardi Therapeutics position peaked at $4K in Q3 2018.
  • 168 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2021.

Based on New Capital Management's 13F filing for Q1 2021, filed 15 Apr 2021.